According to new research from Cardinal Health Specialty Solutions, social detriments of health (SDOH) play an important role in patient outcomes.
More than 90% of oncologists said SDOH such as financial security, access to food, and social isolation are significantly impacting outcomes for cancer patients. The findings provide important insights at a time when the impact of these factors on health are being examined more closely due to the OVID-19 pandemic. These findings were released in the seventh edition of Oncology Insights, a research-based report series analyzing the views of more than 160 U.S. oncologists.
Two-thirds of the participating oncologists said at least half of their patients are negatively impacted by SDOH. Financial insecurity/lack of health insurance was the most cited barrier for patients by far at 83%. Following, access to transportation (58%) and health literacy (53%) were also among the top responses.
The report also featured oncologists’ views on the growing number of cancer survivors. 86% of the respondents agreed that they are seeing a greater number of cancer survivors in their practice than they did five years ago. Nearly three-quarters of the respondents said they need more training in supporting the needs of cancer survivors. Finally, most of the participating oncologists anticipate hiring more advanced practice providers to help manage the growing number of cancer survivors.
The findings in this report are based on web-based surveys conducted in advance of a Cardinal Health Summit held in February 2020, with additional responses also collected via web-based surveys in March and April 2020.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.